Combining tankyrase inhibitors with other targeted therapies, such as PI3K inhibitors (e.g., BKM120) and EGFR inhibitors (e.g., erlotinib), has been proposed as a promising approach for treating APC-mutant colorectal cancers [91,92]. Here, TNKS is linked to colorectal cancer.